• <strike id="xmwty"><table id="xmwty"></table></strike>
    <progress id="xmwty"></progress>

      <b id="xmwty"></b>

      ×

      Tonghua Dongbao’s strategic partner Adocia reports positive clinical trial results for BC Lispro

      Date:2021-01-26
      Author:東寶
      Views:4

      On January 26 (Beijing time), Adocia, a biotechnology company focused on the treatment of diabetes and other metabolic diseases, announced positive results of its clinical trial of the ultra-rapid-acting insulin lispro injection (BC Lispro). Adocia used the insulin lispro drug substances supplied by Tonghua Dongbao in this clinical trial. The positive results prove the performance and quality of Tonghua Dongbao’s insulin lispro drug substances and pave the way for the two companies to carry out the phase III clinical trial in China and the worldwide market.

      Back in 2018, Adocia formed a strategic alliance with Tonghua Dongbao to develop and commercialize BC Lispro in China and other Asian territories. Tonghua Dongbao also supplies insulin lispro and insulin glargine drug substances to Adocia for the worldwide market.

      Previous clinical studies of Adocia demonstrated the faster onset of action and improved glycemic control of BC Lispro, prepared from the insulin lispro drug substances of Eli Lilly and Company, compared to Humalog, Novolog, and Fiasp. BC Lispro also showed great safety and tolerability.

      To advance the phase III clinical trial that studies the BC Lispro prepared from Tonghua Dongbao’s insulin lispro drug substances in Europe and the US, Adocia designed this clinical trial and obtained approvals from the German regulator and the US FDA in July 2020 successively.

      This randomized, crossover, double-blind glucose clamp study was conducted in 30 patients with type 1 diabetes. It evaluated and compared the pharmacodynamic and pharmacokinetic profiles and safety of four formulations, i.e., BC Lispro based on the patented BioChaperone excipient and Tonghua Dongbao’s insulin lispro drug substances, BC Lispro based on the patented BioChaperone excipient and Eli Lilly and Company’s insulin lispro drug substances, Humalog (Eli Lilly and Company) approved in the US, and Humalog (Eli Lilly and Company) approved in Europe.

      The results showed that the BC Lispro based on Tonghua Dongbao’s insulin lispro drug substances demonstrated faster absorption and onset of action with good safety and tolerability than Humalog approved in the US and Europe. In addition, BC Lispro based on Tonghua Dongbao’s insulin lispro drug substances showed similar pharmacodynamic and pharmacokinetic profiles with the BC Lispro prepared from Eli Lilly and Company’s insulin lispro drug substances, which suggests that data from the previous clinical studies can be bridged.

      Olivier Soula, Deputy CEO and R&D Director of Adocia, said this study was an important milestone for Adocia in BC Lispro development, paving the way for the phase III clinical trial in Europe and the US.

      Mr. Leng Chunsheng, Chairman of Tonghua Dongbao, said that the positive clinical trial results are of great value to both parties, and will play a positive role in advancing the phase III clinical trial of BC Lispro, which has already got the NMPA approval, in China. Going forward, Tonghua Dongbao will double down on drug R&D and further enrich its product portfolios to be an explorer and leader of novel drugs R&D in the field of endocrinology.

      0 国产在线看片av免费,91中文字幕 国产,国产丝袜脚足j在线视频播放,黄视频在线观看无码免费
    1. <strike id="xmwty"><table id="xmwty"></table></strike>
      <progress id="xmwty"></progress>

        <b id="xmwty"></b>

        人妻无码在线一二| 亚洲欧美日韩在线一区二区| 99精品全国免费观看视| 亚洲91青草衣衣在线观看| 亚洲中文无码黄片精品视频| 亚洲综合网伊人中文| 不卡的毛片在线视频| 国产精品国产精品国产专区| 无码不卡的中文字幕视频| 九九精品视频在线观看| 亚洲A级无码免费观看| 人妻系列一区二区播放| 亚洲中文av一区二区三区| 曰韩无码无遮挡A级毛片777| 精品一区二区中文性爱视频| 精品日本色一区二区| 青青青青日韩无码一区二区| 狠狠躁夜夜躁人人爽蜜桃| 国产福精品利视频免费| 国产精品亚洲ΑV天堂无码| 国产精品岛国久久久久| 免费看成人国产一区二区三区| 无码国模大尺度视频在线观看| 永久免费无码三级片| 亚洲国产品综合人成综合网站| 亚洲视频在线免费观看| 国产激情国语对白普通话| 国产在线欧美日韩| 国产精品人人做人人爽人人添|